$209.85
1.44%
NYSE, Apr 21, 07:45 pm CET
ISIN
US7611521078
Symbol
RMD

ResMed Stock price

$212.91
-11.83 5.26% 1M
-26.68 11.14% 6M
-15.78 6.90% YTD
+39.08 22.48% 1Y
-19.08 8.22% 3Y
+47.75 28.91% 5Y
+141.03 196.20% 10Y
NYSE, Closing price Thu, Apr 17 2025
+1.42 0.67%
ISIN
US7611521078
Symbol
RMD
Sector

Key metrics

Market capitalization $31.27b
Enterprise Value $31.59b
P/E (TTM) P/E ratio 25.15
EV/FCF (TTM) EV/FCF 22.70
EV/Sales (TTM) EV/Sales 6.41
P/S ratio (TTM) P/S ratio 6.35
P/B ratio (TTM) P/B ratio 5.95
Dividend yield 0.90%
Last dividend (FY24) $1.92
Revenue growth (TTM) Revenue growth 9.38%
Revenue (TTM) Revenue $4.93b
EBIT (operating result TTM) EBIT $1.56b
Free Cash Flow (TTM) Free Cash Flow $1.39b
Cash position $521.94m
EPS (TTM) EPS $8.46
P/E forward 23.28
P/S forward 6.11
EV/Sales forward 6.17
Short interest 6.97%
Show more

Is ResMed a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

ResMed Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a ResMed forecast:

18x Buy
67%
8x Hold
30%
1x Sell
4%

Analyst Opinions

27 Analysts have issued a ResMed forecast:

Buy
67%
Hold
30%
Sell
4%

Financial data from ResMed

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
4,927 4,927
9% 9%
100%
- Direct Costs 2,095 2,095
1% 1%
43%
2,832 2,832
16% 16%
57%
- Selling and Administrative Expenses 734 734
5% 5%
15%
- Research and Development Expense 319 319
5% 5%
6%
1,779 1,779
24% 24%
36%
- Depreciation and Amortization 219 219
2% 2%
4%
EBIT (Operating Income) EBIT 1,560 1,560
28% 28%
32%
Net Profit 1,249 1,249
40% 40%
25%

In millions USD.

Don't miss a Thing! We will send you all news about ResMed directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ResMed Stock News

Neutral
GlobeNewsWire
18 days ago
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, NightOwl™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplified, accurate, and ef...
Neutral
GlobeNewsWire
19 days ago
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2025 on Wednesday, April 23, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may al...
Positive
Seeking Alpha
20 days ago
My Top 15 High-Growth Dividend stocks outperformed SPY and VIG in March, posting a loss of 3.26% compared to SPY's 5.86% and VIG's 4.50%. The April 2025 list offers an average dividend yield of 1.25% and is potentially 31% undervalued, poised for strong long-term returns. Dollar cost averaging into the top 15 stocks each month shows a 68.54% success rate, with 61 out of 89 stocks leading to pos...
More ResMed News

Company Profile

ResMed, Inc. engages in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through the following segments: Sleep and Respiratory Care, and SaaS. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The SaaS segment engages in the supply of business management software as a service to out-of-hospital health providers. Its product portfolio includes devices, diagnostic products, mask systems, headgear and other accessories, and dental devices. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Head office United States
CEO Mick Farrell
Employees 9,980
Founded 1989
Website www.resmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today